Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 4Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Neoplasms 1Mycoses 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × ProMune × Clear all
NCT00199836 2022-10-10

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and MontanideĀ® ISA-51 in Patients With Cancer.

Ludwig Institute for Cancer Research

Phase 1 Completed
14 enrolled 11 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔